Rejoni Receives FDA Approval of the Juveena® Hydrogel System to Reduce Intrauterine Adhesions Following Hysteroscopic Adhesiolysis

[#item_full_content]BEDFORD, Mass.–(BUSINESS WIRE)–Rejoni, Inc., a commercial-stage women’s health company focused on uterine health, today announced that the U.S. Food and Drug Administration (FDA) has granted Premarket Approval (PMA P250051) for the Juveena Hydrogel System. The Juveena Hydrogel System is indicated for use in adult women to reduce the incidence and severity of intrauterine adhesion formation following hysteroscopic adhesiolysis for symptomatic moderate to severe intrauterine adhesions. Intraute